[Seoul = Healthkoreanews] Due to patent expiration of blockbuster products, hypertension treatment market is facing an earthquake-level change.
The outpatient prescription of hypertention treatment for Oct. was 116.2 billion won, decreasing by 7.3% as compared the last year. Drug price reduction of major products and releaes of generic drugs is comsideres as the cause of overall prescription reduction.
The first place was 'Twinstar' of Boehringer Ingelheim, recording 7.1 billion won, an increase of 21.9% as compared with last year, corroborating its stance.
But the second place product is facing change and decrease in prescription due to patent expiration and ranking reshuffle.
As the reexamination period was over last April, Exforge whose generic products were released last October, registerd 6.4 billion won, decresing 6.5% as compared last year. It was not a bad record in consideration of the release od 100 and more generic products were release.
It can be in terpreted as the seasonal effect. As the prescription of hypertention treatment drugs, October prescription of Exforge of Ocober incresed by 4% as coimpared with last September.
The rise of Sevikar boasting of 3-complex composition was conspicuous. It increase by 23.4% as compared with last year and registered 4.7 billion won prescripof tion exceeding Norvascand Olmetec. After the patent-expired Olmetec last September greatly decreased, Sevikar is cementing its stance as the first place in hypertension treatment instantly.
Olmetec decreased by 36.4% as compared with last year, reflecting the effect of generic drugs' invasion.
Hanmi Pharm's amozaltan decresed by 3.6%(4 billion won) but it has retained third place due to the fall of Olmetec.
Besides, Mikardis, expired early this year, and Pritor sustained its increase by recording 35.6% decrease and 39.4% decrease respectively.
Meanwhile, domestic Kanard sustained registerd rise showing 16.3% increase(2.2 billion won) as compared to last year.
Modifiied new drug of Twinstar, Telmineuvo of Chongkeundang registerd 1.1 billion won, showing 10.1% increase, showing its constant rise.
<Republic of Korea medical journal>
